R1 RCM Forms Special Committee to Evaluate Strategic Alternatives
MURRAY, Utah, March 11, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced the formation of a special committee comprised solely of independent directors (the “Special Committee”) to evaluate strategic alternatives in response to the Schedule 13D/A filed by New Mountain Capital, L.L.C.
- MURRAY, Utah, March 11, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced the formation of a special committee comprised solely of independent directors (the “Special Committee”) to evaluate strategic alternatives in response to the Schedule 13D/A filed by New Mountain Capital, L.L.C.
- Consistent with its fiduciary duties, and in consultation with its independent advisors, the Special Committee will carefully review the communications from New Mountain Capital and evaluate strategic alternatives to determine the course of action that it believes is in the best interests of R1 and its stockholders.
- R1 remains focused on providing clients with world-class revenue cycle solutions to help providers improve their financial performance and deliver an exceptional patient experience.
- No assurances can be given regarding the outcome or timing of the Special Committee’s review process.